A Study to Assess the Effect of Seltorexant Compared to Placebo on Respiration During Sleep in Adult Participants With Obstructive Sleep Apnea
- First Posted Date
- 2019-01-08
- Last Posted Date
- 2022-06-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 34
- Registration Number
- NCT03796026
- Locations
- πΊπΈ
NeuroTrials Research, Inc., Atlanta, Georgia, United States
πΊπΈClinilabs, New York, New York, United States
πΊπΈCTI Clinical Trial and Consulting Services, Cincinnati, Ohio, United States
Analysis of Non-Invasively Collected Microneedle Device Samples From Mild Plaque Psoriasis for Use in Transcriptomics Profiling
- Conditions
- Psoriasis Vulgaris
- Interventions
- Device: Microneedle Device
- First Posted Date
- 2019-01-07
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 11
- Registration Number
- NCT03795402
- Locations
- π¨π¦
Innovaderm Research Inc., Montreal, Quebec, Canada
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2018-12-06
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 2517
- Registration Number
- NCT03767244
- Locations
- πΊπΈ
Colorado Clinical Research, Lakewood, Colorado, United States
πΊπΈStamford Hospital, Stamford, Connecticut, United States
πΊπΈMiami Cancer Institute at Baptist Health / Baptist Health Medical Group, Miami, Florida, United States
A Study to Characterize the Clinical Course of Pregnant Women and Children at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn
- Conditions
- Early Onset Severe Hemolytic Disease of the Fetus and Newborn (EOS-HDFN)Erythroblastosis, Fetal
- Interventions
- Other: No intervention
- First Posted Date
- 2018-11-27
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 17
- Registration Number
- NCT03755128
- Locations
- πͺπΈ
Hosp. Univ. San Cecilio, Granada, Spain
π§πͺUniversitair Ziekenhuis Leuven, Leuven, Belgium
π¬π§University College London Hospitals NHSFT, London, United Kingdom
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
- Conditions
- Castration-Resistant Prostatic Cancer
- Interventions
- First Posted Date
- 2018-11-21
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 765
- Registration Number
- NCT03748641
- Locations
- πΊπΈ
Massachusetts General, Boston, Massachusetts, United States
πΊπΈVA Pittsburgh, Pittsburgh, Pennsylvania, United States
πΊπΈComprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
A Study to Evaluate the Safety and Tolerability of JNJ-67670187 in Healthy Participants
- Conditions
- Healthy
- Interventions
- Biological: JNJ-67670187Biological: Placebo
- First Posted Date
- 2018-10-30
- Last Posted Date
- 2020-02-19
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 74
- Registration Number
- NCT03723746
- Locations
- π³π±
PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen, Netherlands
π§πͺClinical Pharmacology Unit, Merksem, Belgium
A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities
- Conditions
- Schizophrenia
- Interventions
- Drug: Risperidone 3 mgDrug: Paliperidone Palmitate 50 mg eq.Drug: Paliperidone Palmitate 175 mg eq.Drug: Paliperidone Palmitate 263 mg eq.Drug: Paliperidone Palmitate 75 mg eq.Drug: Paliperidone Palmitate 350 mg eq.Drug: Paliperidone Palmitate 100 mg eq.Drug: Paliperidone Palmitate 150 mg eq.Drug: Paliperidone Palmitate 525 mg eq.
- First Posted Date
- 2018-10-22
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 34
- Registration Number
- NCT03713658
- Locations
- π·πΌ
Ruhengeri Referral Hospital, Public Hospital, Musanze District, Rwanda
π·πΌCARAES Ndera Neuro-Psychiatric Hospital, Kigali, Rwanda
π·πΌKibungo Referral Hospital, Ngoma District, Rwanda
A Study to Evaluate the Effect of JNJ-53718678 on the Cardiac Repolarization Interval in Healthy Adult Participants
- Conditions
- Healthy
- Interventions
- Drug: JNJ-53718678, 2000 mgDrug: JNJ-53718678, 4500 mg or Dose to be decidedDrug: JNJ-53718678, 3000 mgDrug: JNJ-53718678 500 mgDrug: JNJ-53718678 PlaceboDrug: Moxifloxacin 400 mgDrug: Moxifloxacin Placebo
- First Posted Date
- 2018-10-04
- Last Posted Date
- 2020-02-18
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 52
- Registration Number
- NCT03696459
- Locations
- π§πͺ
Clinical Pharmacology Unit, Merksem, Belgium
A Study to Investigate Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA Gamma 8) Receptor Occupancy of JNJ-64140284 With Newly Developed Transmembrane AMPA Receptor Regulatory Protein (TARP)-Gamma 8 Positron Emission Tomography (PET) [18F]JNJ-64511070 in Healthy Men
- Conditions
- Healthy
- Interventions
- Drug: JNJ-64140284Drug: Fluorine-18 Labeled [18F]-JNJ-64511070
- First Posted Date
- 2018-10-03
- Last Posted Date
- 2019-12-19
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 22
- Registration Number
- NCT03693391
- Locations
- π§πͺ
UZ Leuven Gasthuisberg, Leuven, Belgium
A Study of Seltorexant (JNJ-42847922) After Single-Dose Administration in Healthy Participants
- First Posted Date
- 2018-09-24
- Last Posted Date
- 2020-08-14
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 151
- Registration Number
- NCT03682380
- Locations
- πΊπΈ
PRAHS, Salt Lake City, Utah, United States